Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis.

Li XP, Wen F, Yang W, Deng YB, Li M, Zhang PF, Tang RL, Li Q, Wei YQ.

Tumori. 2014 Jul-Aug;100(4):446-51. doi: 10.1700/1636.17908.

PMID:
25296595
2.

Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.

Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V, Videtic GM.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):197-202. doi: 10.1016/j.ijrobp.2014.05.011. Epub 2014 Jul 8.

PMID:
25015204
3.

Malignant rhabdoid tumor of the liver presented with initial tumor rupture.

Kachanov D, Teleshova M, Kim E, Dobrenkov K, Moiseenko R, Usychkina A, Filin A, Semenkov A, Mitrofanova A, Konovalov D, Shamanskaya T, Novichkova G, Varfolomeeva S.

Cancer Genet. 2014 Sep;207(9):412-4. doi: 10.1016/j.cancergen.2014.04.006. Epub 2014 Apr 21.

PMID:
24894493
4.

Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.

Arakawa Y, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Hanaoka J, Kanamoto M, Iwahashi S, Saito Y, Yamada S, Asanoma M, Takasu C, Bando Y.

Anticancer Res. 2014 Apr;34(4):1953-8.

PMID:
24692731
5.

Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid--enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation.

Han NY, Park BJ, Sung DJ, Kim MJ, Cho SB, Lee CH, Jang YJ, Kim SY, Kim DS, Um SH, Won NH, Yang KS.

Radiology. 2014 May;271(2):416-25. doi: 10.1148/radiol.13131810. Epub 2014 Jan 16.

PMID:
24475862
6.

Raltitrexed-based chemotherapy for advanced colorectal cancer.

Liu Y, Wu W, Hong W, Sun X, Wu J, Huang Q.

Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):219-25. doi: 10.1016/j.clinre.2013.11.006. Epub 2013 Dec 30. Review.

PMID:
24388340
7.

Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.

Morris-Stiff G, White AD, Gomez D, Cameron IC, Farid S, Toogood GJ, Lodge JP, Prasad KR.

Eur J Surg Oncol. 2014 Aug;40(8):1016-20. doi: 10.1016/j.ejso.2013.09.015. Epub 2013 Nov 1.

PMID:
24370284
8.

CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.

Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.

Int J Antimicrob Agents. 2014 Mar;43(3):292-6. doi: 10.1016/j.ijantimicag.2013.10.022. Epub 2013 Nov 25.

PMID:
24359841
9.

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

Azim HA Jr, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG Jr, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart M, de Azambuja E.

J Clin Oncol. 2013 Dec 20;31(36):4504-11. doi: 10.1200/JCO.2013.50.9448. Epub 2013 Nov 18. Erratum in: J Clin Oncol. 2014 Feb 1;32(4):365.

10.
11.

Evaluation of the usefulness of the indocyanine green clearance test for chemotherapy-associated liver injury in patients with colorectal cancer liver metastasis.

Wakiya T, Kudo D, Toyoki Y, Ishido K, Kimura N, Narumi S, Kijima H, Hakamada K.

Ann Surg Oncol. 2014 Jan;21(1):167-72.

PMID:
23959055
12.

Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias.

Lichter-Konecki U, Nadkarni V, Moudgil A, Cook N, Poeschl J, Meyer MT, Dimmock D, Baumgart S.

Mol Genet Metab. 2013 Aug;109(4):354-9. doi: 10.1016/j.ymgme.2013.05.014. Epub 2013 May 29.

PMID:
23791307
13.

Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.

Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, White SA, Mann DA.

J Hepatol. 2013 Aug;59(2):318-26. doi: 10.1016/j.jhep.2013.04.014. Epub 2013 Apr 23.

14.

An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.

Robinson SM, Mann J, Manas DM, Mann DA, White SA.

HPB (Oxford). 2013 Aug;15(8):581-7. doi: 10.1111/hpb.12010. Epub 2012 Dec 27.

15.

Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.

Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T.

Anticancer Drugs. 2013 Apr;24(4):422-5. doi: 10.1097/CAD.0b013e32835efe78.

PMID:
23407060
16.

A reproducible, clinically relevant, intensively managed, pig model of acute liver failure for testing of therapies aimed to prolong survival.

Lee KC, Palacios Jimenez C, Alibhai H, Chang YM, Leckie PJ, Baker LA, Stanzani G, L Priestnall S, Mookerjee RP, Jalan R, Davies NA.

Liver Int. 2013 Apr;33(4):544-51. doi: 10.1111/liv.12042. Epub 2013 Jan 20.

PMID:
23331547
17.

Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.

Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA.

HPB (Oxford). 2013 Feb;15(2):106-15. doi: 10.1111/j.1477-2574.2012.00558.x. Epub 2012 Sep 24.

18.

Protective effect of grape seed proanthocyanidins against liver ischemic reperfusion injury: particularly in diet-induced obese mice.

Song X, Xu H, Feng Y, Li X, Lin M, Cao L.

Int J Biol Sci. 2012;8(10):1345-62. doi: 10.7150/ijbs.4699. Epub 2012 Oct 27.

19.

Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis.

Robinson SM, Wilson CH, Burt AD, Manas DM, White SA.

Ann Surg Oncol. 2012 Dec;19(13):4287-99. doi: 10.1245/s10434-012-2438-8. Epub 2012 Jul 6. Review.

20.

Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.

Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA; COINS Study Team.

HIV Clin Trials. 2012 Mar-Apr;13(2):61-9. doi: 10.1310/hct1302-61.

PMID:
22510353
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk